Skip header and navigation

2 records – page 1 of 1.

Adalimumab therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35127
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1207
Available Online
View Pamphlet
Your health care provider feels that treatment with adalimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (11 p.) : digital, PDF file
Subjects (MeSH)
Adalimumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Specialty
Medications
Abstract
Your health care provider feels that treatment with adalimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Notes
Previous title: Adalimumab (Humira) therapy
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1207
Less detail
Nova Scotia Health Authority. QEII. Cardiology. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
1496
Available Online
View Pamphlet
Ticagrelor is a medicine used along with low dose Aspirin to reduce your risk of having a heart attack. You should not take Ticagrelor if you have or had a current bleeding problem such as bleeding from a stomach ulcer or if you have severe liver disease. Instructions for how to take and store this medicine as well as drug interactions and foods to avoid are discussed. Missed dose instructions are given. This pamphlet also describes warnings and possible side effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. QEII. Cardiology
Alternate Title
Brilinta
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Platelet Aggregation Inhibitors - therapeutic use
Adenosine - therapeutic use
Cardiovascular Diseases - prevention & control
Myocardial Infarction - prevention & control
Pulmonary Embolism - prevention & control
Subjects (LCSH)
Adenosine
Anticoagulants (Medicine)
Cardiovascular system--Diseases--Prevention
Myocardial infarction--Prevention
Abstract
Ticagrelor is a medicine used along with low dose Aspirin to reduce your risk of having a heart attack. You should not take Ticagrelor if you have or had a current bleeding problem such as bleeding from a stomach ulcer or if you have severe liver disease. Instructions for how to take and store this medicine as well as drug interactions and foods to avoid are discussed. Missed dose instructions are given. This pamphlet also describes warnings and possible side effects.
Responsibility
Prepared by: Cardiology
Pamphlet Number
1496
Less detail